Harrow, Inc. (HROW) Emerges as Eye Care Powerhouse With Biosimilars to Lucentis and Eylea

We recently compiled a list of the 11 Best Pharma Stocks to Invest in for the Long Term. Harrow, Inc. is one of them.

Harrow, Inc. (NASDAQ:HROW), a leading U.S.-based pharmaceutical company, is entering a transformative phase as it expands its presence in ophthalmic disease management and is among the best pharmaceutical stocks. With a focus on both anterior and posterior eye conditions, the company has built a diverse portfolio that includes branded drugs, compounded formulations, and now biosimilars, moves that are solidifying its leadership in the fast-growing eye care market.

A key development in 2025 was Harrow, Inc. (NASDAQ:HROW)’s agreement with Samsung Bioepis, granting it exclusive U.S. rights to a portfolio of ophthalmology biosimilars. The deal includes FDA-approved drugs such as BYOOVIZ, referencing Lucentis, and OPUVIZ, referencing Eylea, two of the most widely prescribed anti-VEGF therapies for retinal disorders. With roughly 8.5 million units of anti-VEGF treatments administered annually, the addition of these biosimilars immediately diversifies the business’s offerings and positions it to compete with established industry leaders.

Beyond biosimilars, Harrow, Inc. (NASDAQ:HROW) is also advancing its branded portfolio. The corporation recently acquired rights to BYQLOVI, a clobetasol propionate ophthalmic suspension approved for post-surgical inflammation and pain. Expected to launch in early 2026, BYQLOVI marks the first new ophthalmic steroid in its category in more than 15 years. At the same time, patient access initiatives such as the VAFA (VEVYE Access for All) program and the Harrow Cares HUB are expanding coverage and reimbursement support for treatments like VEVYE and IHEEZO, further boosting adoption.

Looking ahead, Harrow, Inc. (NASDAQ:HROW) expects continued momentum in 2025 and 2026 as both new branded therapies and biosimilars gain traction.

While we acknowledge the potential of HROW as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure. None.